When your headphones should stay put: iOS 26’s little setting that matters more than you think

Ever had that jolt of embarrassment when your podcast — or worse, your midnight karaoke — suddenly starts booming through the car speakers as you climb in? Or fallen asleep with your AirPods on only to wake up to silence because your phone auto-switched? iOS 26 quietly fixes one of those tiny, annoying interruptions with a toggle that deserves a place on every AirPods user's settings screen.

Why this matters more than it sounds

We live in an ecosystem where devices are supposed to make things seamless. But “seamless” became a problem when your iPhone decided to be helpful by switching audio to whatever Bluetooth device it connected to next — often your car or a speaker — without asking. That handoff can be harmless, awkward, or flat-out embarrassing depending on the context.

iOS 26 introduces a new option that gives control back to you: keep your audio in your headphones until you explicitly move it elsewhere. For people who use AirPods while commuting, exercising, or winding down at night, that’s a tiny change with a big quality-of-life payoff.

What the setting does (and where to find it)

• Name: Keep Audio with Headphones.
• What it does: Prevents your iPhone from automatically rerouting audio from your headphones to other devices (CarPlay, car Bluetooth, speakers) when it connects to them.
• Where it lives: Settings > General > AirPlay & Continuity > Keep Audio with Headphones. Toggle it on.

This is a system-level setting, not limited to Apple’s own buds — it works for AirPods and most other Bluetooth headphones.

Who should turn it on

• Nighttime listeners and nap-timers

  • If you fall asleep wearing AirPods, this setting helps avoid sudden switches that interrupt sleep or stop the audio unexpectedly. Combined with iOS features that can pause audio when sleep is detected, it makes listening while dozing much less fragile.

• Commuters and privacy-minded users

  • If you want a private call or podcast to stay private when you step into a vehicle, this keeps the audio in your ears until you choose otherwise.

• People who jump between Apple devices (but not always intentionally)

  • Auto-switching across iPhones, Macs, and iPads is handy — but not when it happens at the worst time. This setting lets you keep the output anchored.

A couple of caveats

• Manual switching still works

  • With the setting on you can always move audio to your car or speakers manually through Control Center or CarPlay. The setting just stops the phone from doing it automatically.

• It’s not a safety endorsement

  • Using earbuds while driving can be illegal or unsafe in some places. The setting doesn’t change local laws or safety recommendations — it just prevents unwanted audio handoffs.

• Behavior can vary by device & firmware

  • Some users report differences depending on car systems and Bluetooth stack behaviors; generally, the setting improves predictability, but your mileage may vary.

A broader trend: Apple tightening up audio control

iOS 26 isn’t just about this toggle. Apple has been rolling out a series of refinements that make audio behavior more sensible — from improved AirPods gestures and camera controls to sleep-aware audio pausing and smarter device switching. The “Keep Audio with Headphones” option fits into a larger pattern: give users simple, explicit controls for things the OS used to guess about automatically.

Small change, big comfort

For a feature that’s easy to miss, this one is quietly powerful. It’s the kind of fix that doesn’t make headlines but saves you from small moments of irritation — and, for people who fall asleep with their earbuds in, preserves a peaceful night.

A quick checklist

• Want private playback that won’t hop to your car? Turn it on.
• Sleep with AirPods and hate sudden silence? Turn it on.
• Prefer the system to decide automatically? Leave it off.

My take

I love features that respect the user’s intent rather than guessing for them. This toggle is a great example of Apple listening to the little frustrations that add up. It doesn’t reinvent the wheel — it simply stops the wheel from rolling away when you don’t want it to. If you wear AirPods (or any Bluetooth buds) regularly, it’s worth flipping on and forgetting about it.

Sources

• Keep Audio with Headphones — Apple Support.
  https://support.apple.com/en-afri/104988

• iOS 26: Keep AirPods Connected When You Get in Your Car — MacRumors.
  https://www.macrumors.com/how-to/ios-keep-airpods-connected-get-in-your-car/

• A new iPhone setting will stop CarPlay from stealing your AirPods’ audio — The Verge.
  https://www.theverge.com/news/796554/iphone-ios-26-keep-airpods-wireless-headphones-connected-carplay

Medicare just picked 15 big-name drugs for steep price cuts — here's what it means

The headline alone is a jaw-dropper: Medicare will pay less for 15 high-cost medicines — including household names like Ozempic, Wegovy and several cancer treatments — after the latest round of negotiations under the Inflation Reduction Act. That change, announced by the Centers for Medicare & Medicaid Services, is scheduled to take effect January 1, 2027, and CMS says the negotiated prices would have shaved billions off last year’s spending if they’d already been in place. (cms.gov)

Why this matters right now

• Drug prices are a top worry for older Americans and people with chronic illnesses; Medicare Part D covers many of the therapies on this list.
• The Medicare negotiation program — born out of the Inflation Reduction Act of 2022 — is moving from pilot to policy: this is the second batch of negotiated drugs, bringing the total with final prices to 25. (cms.gov)
• Some of the medicines targeted are among the fastest-growing sellers in the pharmaceutical market (notably GLP-1 drugs for diabetes and weight loss), so the political and commercial ripples will be big. (washingtonpost.com)

A quick snapshot of what's on the list

• GLP-1 drugs: Ozempic, Wegovy, Rybelsus (diabetes and weight-loss).
• Asthma/COPD inhalers: Trelegy Ellipta, Breo Ellipta.
• Cancer drugs: Xtandi, Pomalyst, Ibrance, Calquence.
• Other chronic-disease drugs: Janumet (diabetes), Tradjenta, Otezla (psoriatic arthritis), Linzess (IBS), Xifaxan, Austedo (movement disorders), Vraylar (psychiatric). (cms.gov)

What the price cuts actually look like

CMS reports negotiated discounts ranging widely — from substantial (dozens of percent off list price) to very large (some as high as about 70% for certain GLP-1 drugs in reporting). CMS estimates these second-round deals would have reduced Medicare spending by billions in a single year and projects material out-of-pocket relief for beneficiaries once the prices take effect. Exact monthly/annual costs for individual patients will still depend on their plan design and whether the manufacturer participates in the finalized deals. (cms.gov)

The stakes for patients, companies and taxpayers

• Patients: Lower Medicare-negotiated prices should reduce out-of-pocket costs for many seniors who use these drugs, especially those who reach catastrophic spending. CMS also pointed to a broader out-of-pocket cap in Part D that complements these negotiations. (cms.gov)
• Drugmakers: These negotiations can cut into revenues for blockbuster medicines, prompting pushback from industry — from public relations campaigns to lawsuits. Companies can choose to participate in negotiations (and accept a lower “maximum fair price”) or refuse and face penalties such as excise taxes or exclusion from Medicare markets. (cms.gov)
• Taxpayers/government: CMS frames the moves as meaningful federal savings; independent analysts and outlets have produced different estimates, but the consensus is these rounds will save Medicare and beneficiaries billions over time. (cms.gov)

The practical complications to watch

• Timing and transitions: Negotiated prices become effective January 1, 2027. Until then, current list/pricing structures remain in place, and insurers will have to adjust formularies and cost-sharing schedules ahead of implementation. (cms.gov)
• Manufacturer responses: History suggests some companies will litigate or otherwise resist; others may negotiate quietly. That can affect availability, manufacturer assistance programs, and how quickly savings reach patients. (apnews.com)
• Market effects: Large discounts on GLP-1s and other best-sellers could shift prescribing patterns, spur competition, and influence drug development priorities. How innovation incentives change is a central political and economic debate. (washingtonpost.com)

What to watch next

• Implementation details from CMS and Plan Sponsors: how Part D plans will show beneficiary savings (copays vs. coinsurance), and whether manufacturers alter patient support programs.
• Legal challenges from manufacturers and any court rulings that could delay or reshape the program.
• Market responses: price moves on competing therapies, potential shifts in formulary placement, and whether private insurers seek similar negotiated prices.

Quick takeaways for readers

• These negotiations are real, targeted, and scheduled to take effect Jan 1, 2027. (cms.gov)
• The second round covers 15 drugs used for diabetes, weight loss, cancer, asthma and other chronic conditions — many are widely used and high-spend items for Medicare. (cms.gov)
• Expected savings are large in aggregate but will vary for individual patients based on their plan and whether they hit the new out-of-pocket cap. (cms.gov)

My take

This moment is a practical test of a policy born from the Inflation Reduction Act: can government negotiation deliver meaningful relief without tangling the market in legal and logistical knots? The answer will be messy at first — implementation always is — but millions of Medicare beneficiaries stand to gain tangible relief if the rules play out as CMS projects. The bigger policy conversation — balancing affordability with incentives for pharmaceutical innovation — will continue to be fought in courtrooms, boardrooms and Congress. For now, patients facing high drug bills should follow their plan notices and work with providers and pharmacists to understand the impacts once 2027 approaches. (cms.gov)

Sources

• CMS: CMS Delivers Savings for Seniors on 15 Major Drugs for Cancer and Chronic Disease
  https://www.cms.gov/newsroom/press-releases/cms-delivers-savings-seniors-15-major-drugs-cancer-chronic-disease (cms.gov)

• HHS/CMS announcement: HHS Announces 15 Additional Drugs Selected for Medicare Drug Price Negotiations
  https://www.cms.gov/newsroom/press-releases/hhs-announces-15-additional-drugs-selected-medicare-drug-price-negotiations-continued-effort-lower (cms.gov)

• Washington Post: Weight-loss, cancer drugs among 15 to get lower Medicare pricing, U.S. says
  https://www.washingtonpost.com/health/2025/11/26/trump-medicare-drug-prices-ozempic/ (washingtonpost.com)

• AARP explanation: The Next 15 Costly Drugs Medicare Will Be Negotiating
  https://www.aarp.org/medicare/more-medicare-drug-price-negotiations-2025/ (aarp.org)

• KPBS Public Media coverage: Medicare negotiated lower prices for 15 drugs, including 71% off Ozempic and Wegovy
  https://www.kpbs.org/news/health/2025/11/26/medicare-negotiated-lower-prices-for-15-drugs-including-71-off-ozempic-and-wegovy (kpbs.org)

A new blade in Pokémon GO: Shiny Keldeo arrives with Pony Tales Masterwork Research

The moment many Trainers have been waiting for is here: Pokémon GO is finally giving players a shot at Shiny Keldeo — and it’s arriving on a paid Masterwork Research track tied to the Final Justice event. Whether you’re a completionist, a collector, or just curious how the paid track works, here’s a friendly walkthrough and my take on whether the ticket is worth it.

Quick hits you can scan

• Event window: November 25, 2025 at 10:00 a.m. local time through November 30, 2025 at 8:00 p.m. local time. (pokemongo.com)
• Shiny debut: Shiny Keldeo makes its Pokémon GO debut via the Pony Tales Masterwork Research ticket. (pokemongohub.net)
• Ticket price and availability: Masterwork Research ticket (Pony Tales) available in-game for US$7.99 (or equivalent) between Nov 25–30, 2025. Ticket is nonrefundable and cannot be bought with PokéCoins. Masterwork Research itself does not expire after purchase. (pokemongo.com)
• Resolute Form: The Final Justice event also unlocks the final Seasonal Special Research allowing players to change Keldeo into Resolute Form (requires 50 Keldeo Candy) and teaches it Secret Sword. (pokemongo.com)

Why this matters (and why it feels a bit different)

Keldeo is a Gen‑V mythical with high aesthetic and collector appeal. Historically, Mythical Pokémon and their rare forms are among the most sought-after catches in Pokémon GO, and a Shiny debut is a calendar moment for many players. What changes the dynamics this time is the distribution method: a paid Masterwork Research ticket.

Masterwork Research tracks in Pokémon GO are designed to be longer, premium research lines. They usually pack guaranteed encounters, cosmetics, and sometimes exclusive rewards. The trade-off: you pay up front but can complete it at your own pace (it does not expire after purchase). For Shiny-seekers, that guaranteed encounter is often the main draw.

What the Pony Tales Masterwork Research includes

• A paid ticket (Pony Tales Masterwork Research) sold in the in‑game shop during the Final Justice event period. (pokemongohub.net)
• Encounters with Keldeo (including the opportunity to encounter a Shiny Keldeo). (pokemongohub.net)
• Ancillary encounters and rewards tied into the event’s field research, raids, and themed spawns (e.g., Hitmonlee/Hitmonchan/Hitmontop increases and their shinies). (pokemongo.com)
• An Ultra Ticket box option highlighted by some outlets that bundles the ticket with extra items (Premium Battle Pass, Star Piece) for the listed price. Details and availability vary by region and are listed in the shop during the event. (pokemongohub.net)

Important dates and purchase details (be precise)

• Ticket sale window: November 25, 2025 at 10:00 a.m. local time — November 30, 2025 at 8:00 p.m. local time. You must purchase during that window, but once purchased, the Masterwork Research does not expire so you can finish it later. (pokemongo.com)
• Final claim window for the Seasonal Special Research: you can claim the final chapter (which unlocks Resolute Form) up to December 2, 2025 at 10:00 a.m. local time. (pokemongo.com)

Is the ticket worth the price?

Consider these factors when deciding:

• Collector priority: If you want a Shiny Keldeo in your dex, the ticket gives a direct pathway to that encounter. For collectors, a guaranteed chance often justifies the fee.
• Price sensitivity: US$7.99 for a guaranteed Shiny encounter is on the lower side compared with some big-ticket event passes, but it’s still a paid gate. If you don’t care for shinies or can wait for other distribution methods, skipping is fine. (pokemongo.com)
• Time flexibility: Because Masterwork Research doesn’t expire, you can pace the tasks — good for casual players or those with limited play time. (pokemongo.com)
• Extra value: Look at the Ultra Ticket box (if shown in your shop) — bundles sometimes include Premium Battle Passes and Star Pieces that boost XP or catch rewards, which can add value if you plan to raid or grind during the event. (pokemongohub.net)

My practical take: for a Trainer who values dex completion and shinies, US$7.99 for a long-term, guaranteed path to Shiny Keldeo is a reasonable price. If you’re budget-conscious and indifferent to missing a Shiny, wait and see—Keldeo might become available through other special research later, but a Shiny debut is often rare to repeat quickly.

Tips to get the most from Final Justice and the Masterwork Research

• Buy early during the sale window if you know you want the ticket — it must be purchased between Nov 25–30, 2025. (pokemongo.com)
• If an Ultra Ticket bundle is offered, compare the included items against what you’d buy separately (Premium Battle Passes are useful if you plan to raid). (pokemongohub.net)
• Save Keldeo Candy once Resolute Form becomes available (you’ll need 50 candy to change form). If you already have Keldeo from past research, consider transferring duplicates wisely. (pokemongo.com)
• Don’t forget other event benefits: increased shiny chances for Hitmonlee/Hitmonchan/Hitmontop and free raid passes from spinning Gyms during the event window. These are nice extras while you’re out playing. (pokemongo.com)

My take

Niantic’s move to debut shinies on paid research tracks keeps things interesting. It’s a compromise between accessibility and monetization: players willing to pay get a clean, guaranteed path to a rare catch, while others can still enjoy the event’s free content and hope for alternative chances later. For collectors and shinies hunters, this is a can’t-miss moment — and at US$7.99, it’s a modest investment for a potentially rare trophy.

Final thoughts

Shiny Keldeo’s debut is a highlight for 2025’s Tales of Transformation finale. The Pony Tales Masterwork Research is straightforward and player-friendly in that the research doesn’t expire after purchase. If you’ve been holding out for this shiny, the ticket gives you the clearest route. If not, the rest of the event still offers worthwhile spawns and rewards — and Keldeo’s new Resolute Form and Secret Sword add a fun competitive twist.

Sources

• Finish off Tales of Transformation with the Final Justice event, Keldeo’s Resolute Form, and Keldeo’s Shiny debut! — Pokémon GO News
  https://pokemongo.com/news/final-justice-2025 (pokemongo.com)

• Pony Tales Masterwork Research: Shiny Keldeo — Pokémon GO Hub
  https://pokemongohub.net/post/guide/pony-tales-masterwork-research-shiny-keldeo (pokemongohub.net)

• Final Justice (event overview) — Pokémon GO Hub
  https://pokemongohub.net/post/event/pokemon-go-final-justice-event (pokemongohub.net)